February 22, 2021
This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market.
twitter chat
September 28, 2020
IGBA released a new policy paper about developing a regulatory framework supporting biosimilar competition.
biosimilars in the pharmacy
July 16, 2020
Biosimilars in the pharmacy benefit employers driving appropriate use and transparency.
europe's biosimilars market
June 3, 2020
This paper delves into the lessons the United States should adopt to speed the development of its market while also highlighting European market pitfalls to avoid.
barriers to biosimilar adoption
September 9, 2019
This white paper will provide an explanation to the perverse mixture of brand-name biologic companies’ anti-competitive market access tactics and inadequate incentives that have cost the U.S. health care system billions of dollars in lost savings.
June 25, 2019
The Association for Accessible Medicines (AAM) Biosimilars Council found that delayed entry of biosimilars due to patenting has cost the U.S. health care system an astounding $7.6 billion in lost savings since 2015.

Recent Tweets

Proposals included in #BuildBackBetter undermine the progress and promise of future #biosimilar savings, particularly for employers and patients in commercial health insurance markets.

Learn more in our latest blog post:

Load More...